Toronto, Ontario – June 18, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF:OTC Pink®), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that it will present at the Biotechnology Industry Organization (“BIO”) Conference on Thursday, June 18, 2015 at the Pennsylvania Convention Center in Philadelphia, Pennsylvania. The Company’s presentation by Roger Dumoulin-White, President & CEO is scheduled to begin at 10:30 am ET. About BIO Exhibition: The world’s largest biotechnology gathering, the BIO exhibition allows exhibitors to reach high-level executives and influential decision makers who come to BIO to discover new players in the industry, form partnerships and evaluate emerging technologies. The 2015 BIO exhibition will feature more than 1,700 exhibitors and approximately 160,000 square feet. The exhibition also includes 60+ state, regional and country pavilions who in turn host many companies from their regions. About Theralase Technologies Inc. … Read More

Toronto, Ontario – June 11, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF:OTC Pink®), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that it has released commercial versions of its next generation therapeutic laser to its team of Key Opinion Leaders (“KOLs”) and Territory Sales Managers (“TSMs”) for evaluation only purposes. Formal Health Canada approval is expected in early July 2015, allowing commercial sale of the TLC-2000 in Canada. The patented TLC-2000 next generation therapeutic laser sets a new standard in cold laser therapy with its patented Cell SensingTM technology. This technology “senses” the exact location of injured tissue in a body and then automatically adjusts for a patient’s physical characteristics to deliver an optimized dose of laser light energy to heal the injury faster and more effectively than any other laser product on the market. Roger Dumoulin-White, President … Read More

Toronto, Ontario – June 10, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF:OTC Pink®), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that its next generation therapeutic laser, the TLC-2000, has recently received safety approval from the Canadian Standards Association (“CSA”).  CSA conducted an in-depth review of the Company’s technical testing results and approved the product in accordance with the latest international medical standards, including Canadian and US standards. The CSA safety approval paves the way for formal Health Canada approval anticipated in early July 2015. The patented TLC-2000 next generation therapeutic laser sets a new standard in cold laser therapy with its patented Cell SensingTM technology. This technology “senses” the exact location of injured tissue in a body and then automatically adjusts for a patient’s physical characteristics to deliver an optimized dose of laser light energy to heal … Read More

Toronto, Ontario – May 29, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT: TSXV) (TLTFF: OTC Pink®), a medical laser company dedicated to commercializing technology to heal pain and destroy cancer, released its first quarter 2015 financial results today, demonstrating an increase of 2% in revenue year over year. In 2014 and early 2015, Theralase has made dramatic strides in both its Therapeutic Laser Therapy (“TLT”) and Photo Dynamic Therapy (“PDT”) anti-cancer divisions. In the TLT division, Theralase has completed the design and initial manufacture of its next generation TLC-2000 therapeutic laser technology and is currently awaiting final Health Canada approval to launch in Canada. The TLC-2000, with patented Cell SensingTM technology, is able to determine the precise location of injured tissue in a patient based upon their physical characteristics and automatically deliver an optimal dose of healing laser light energy safely and effectively to heal the damaged tissue … Read More

Toronto, Ontario – May 28, 2015 Theralase Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (TLTFF: OTC Pink®), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that it has granted an aggregate of 4,200,000 stock options to directors and officers at an exercise price of $CAN 0.50 vesting over three years and expiring five years from date of issue. These stock options were granted to directors and officers in compliance with the Company’s 2004 Stock Option Plan approved by the shareholders of the Corporation at the Annual General and Special Meeting held on November 14, 2014. These stock options were granted as a means of rewarding directors and officers for future service to the Corporation, including: Launch of the patented TLC-2000 biofeedback therapeutic laser system with Cell SensingTM technology in 2Q2015 and Commencement of the Health Canada Phase Ib human clinical … Read More

Toronto, Ontario – May 27, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF: OTC Pink®), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, presented its latest scientific research at the 15th International Photodynamic Association (“IPA”) World Congress in Rio De Janeiro, Brazil from May 22 to 26, 2015. The latest research details the dramatic increase in targeting and efficacy in the destruction of cancer of Theralase’s lead Photo Dynamic Compound (“PDC”) TLD-1433 when bound to transferrin, in a presentation entitled, “Novel biophysical properties of photosensitizer TLD-1433 upon binding to transferrin”   About IPA: The IPA was founded in 1986 and its membership consists of the most prominent international clinicians and scientists involved in performing and researching Photo Dynamic Therapy (“PDT”) and Photo Diagnosis (“PD”). The purpose of the IPA is to promote the study of diagnosis and treatment using light and … Read More

Toronto, Ontario – May 26, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF:OTC Pink®), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that it will present at the 2015 Marcum MicroCap Conference on Wednesday, May 27, 2015 at the Grand Hyatt Hotel in New York City. The Company’s presentation by Roger Dumoulin-White, President & CEO is scheduled to begin at 1:30 pm ET and will be available via live webcast. To access the webcast, please visit http://wsw.com/webcast/marcum3/tltff About the Marcum MicroCap Conference The Marcum MicroCap Conference is dedicated to providing a forum where publicly traded companies under $500 million in market capitalization can network with the investment community. The conference features presentations by CEOs and CFOs from six principal industry sectors and provides investors with the opportunity to meet with management of these companies on a one-on-one basis. Industry … Read More

Toronto, Ontario – May 14, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF: OTC Pink®), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, has discovered that its lead anti-cancer drug, TLD-1433, emits a fluorescent signature when light activated in a Non-Muscle Invasive Bladder Cancer (“NMIBC”) animal model. The advantages of this discovery are three fold: It can be used as a diagnostic tool for the oncologist to detect the presence of cancer cells and micro-metastases too small to be seen by the human eye. It can be used to determine sufficient uptake of TLD-1433 into the cancer cells After light activation, it can determine if the cancer cells that have absorbed the drug have been destroyed. Theralase intends to use this new discovery in the treatment of NMIBC. Clinical Treatment Protocol of NMBIC with Photo Dynamic Therapy: Intravesical installation of TLD-1433 … Read More

Toronto, Ontario – May 12, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF: OTC Pink®), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that it has successfully manufactured its lead, light-activated, anti-cancer drug, TLD-1433, specifically developed for the treatment of cancer, to high purity levels. Drugs intended for in human clinical applications, such as TLD-1433, must be manufactured in accordance with Good Manufacturing Practices (“GMP”) standards. To achieve GMP standards, the normal manufacturing process involves “scaling-up” the production from small quantities to successively larger quantities to optimize the purity and yield of the drug to arrive at a commercial grade product, suitable for human applications. In April 2015, Theralase announced the completion of the manufacture of its lead anti-cancer drug in pre-commercial quantities. The Company has now completed another critical step, optimization of the manufacturing process to produce high … Read More

Toronto, Ontario – May 1, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT: TSXV) (TLTFF: OTC Pink®) released its 2014 financial results today, demonstrating an increase of 15% year over year in revenue. In 2014 and early 2015, Theralase has made dramatic strides in both its Therapeutic Laser Therapy (“TLT”) and Photo Dynamic Therapy (“PDT”) anti-cancer divisions. In the TLT division, Theralase has completed the design and initial manufacture of its next generation TLC-2000 therapeutic laser technology and is currently awaiting final Health Canada approval to launch in Canada. The TLC-2000 with patented Cell SensingTM technology is able to determine the precise location of injured tissue in a patient based upon their physical characteristics and automatically deliver an optimal dose of healing laser light energy safely and effectively to heal the damaged tissue faster and more effectively than any other laser system on the market. In the PDT division, … Read More